Know Labs (NYSE:KNW) announced today that it received a new patent equating its diagnostic technology to the current glucose monitoring standard.
Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It integrate into wearable, mobile or bench-top form factors. The first application of the technology comes in the form of a non-invasive glucose monitor.
The company’s new patent equates the technology to mean absolute relative difference, or MARD. This standard, used by diabetes researchers and glucose meter makers, establishes a range of clinical accuracy. Know Labs said the patent expands its IP portfolio to nearly 90 patents issued and pending.
“Intellectual property development is a critical pillar of our success,” said Ron Erickson, Know Labs founder and chair. “We make significant investments in the strategic development of our IP portfolio, which creates long-term value for our shareholders, improves our competitive position and accelerates our efforts to bring the first FDA-cleared, truly non-invasive glucose monitoring device to the market.”
This patent explicitly designates a MARD range between 5% and 9.9% for the non-invasive diagnostics platform. It falls equal to superior to MARD readings of any FDA-cleared blood glucose monitoring products, Know Labs said.
More about the Know Labs glucose monitoring technology
Bio-RFID technology uses time-frequency synchronization and decoupled antenna designs.
Know Labs said this enables the collection of a “massive amount” of data signals across real-time glucose concentrations. These cover interstitial fluid, capillary and venous blood and cellular tissue. The company said its sensor penetrates to an average of 0.5 inches, based on internal estimates. This compares to the typical penetration of 0.2 inches with common minimally invasive CGMs, the company added.
The company said its non-invasive technology could “become the new reference standard for glucose testing.”
“We believe this is the first and only patent granted with a MARD range in its claims,” Erickson added. “This is a significant milestone for Know Labs and for the non-invasive glucose monitoring industry, as it sets a new benchmark for MARD among all glucose sensors, invasive or not. We remain highly confident in our plans as we continue executing toward the FDA clearance process.”